Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Oldenburg

Showing results (1-10 of 440) with videos related to

Pageof 44
Sort By:
Thrombosis Research|November 30, 2010
Prophylaxis in bleeding disordersJohannes Oldenburg
The New England Journal of Medicine|October 5, 2022
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia BJohannes Oldenburg
Blood|February 26, 2015
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimensJohannes Oldenburg
Thrombosis and Haemostasis|May 12, 2005
Vitamin K intake and stability of oral anticoagulant treatmentJohannes Oldenburg
Hamostaseologie|February 19, 2026
GTH 2026: Connected Science - Advanced SolutionsJohannes Oldenburg, Bernd Pötzsch
Seminars in Thrombosis and Hemostasis|September 13, 2013
Defining severity of hemophilia: more than factor levelsAnna Pavlova, Johannes Oldenburg
Hamostaseologie|January 23, 2020
The Current Understanding of Molecular Pathogenesis of Quantitative von Willebrand Disease, Types 1 and 3Hamideh Yadegari, Johannes Oldenburg
Hamostaseologie|December 18, 2013
[Hamburg Hemophilia Symposium 2012]Johannes Oldenburg, Karin Kurnik
The New England Journal of Medicine|November 25, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsJohannes Oldenburg, Gallia G Levy
Thrombosis Research|September 30, 2014
Prophylaxis in adult patients with severe haemophilia AJohannes Oldenburg, Hans-Hermann Brackmann
Pageof 44

Showing results (1-10 of 440) with videos related to

Sort By:
Pageof 44
Thrombosis Research|November 30, 2010
Prophylaxis in bleeding disordersJohannes Oldenburg
The New England Journal of Medicine|October 5, 2022
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia BJohannes Oldenburg
Blood|February 26, 2015
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimensJohannes Oldenburg
Thrombosis and Haemostasis|May 12, 2005
Vitamin K intake and stability of oral anticoagulant treatmentJohannes Oldenburg
Hamostaseologie|February 19, 2026
GTH 2026: Connected Science - Advanced SolutionsJohannes Oldenburg, Bernd Pötzsch
Seminars in Thrombosis and Hemostasis|September 13, 2013
Defining severity of hemophilia: more than factor levelsAnna Pavlova, Johannes Oldenburg
Hamostaseologie|January 23, 2020
The Current Understanding of Molecular Pathogenesis of Quantitative von Willebrand Disease, Types 1 and 3Hamideh Yadegari, Johannes Oldenburg
Hamostaseologie|December 18, 2013
[Hamburg Hemophilia Symposium 2012]Johannes Oldenburg, Karin Kurnik
The New England Journal of Medicine|November 25, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsJohannes Oldenburg, Gallia G Levy
Thrombosis Research|September 30, 2014
Prophylaxis in adult patients with severe haemophilia AJohannes Oldenburg, Hans-Hermann Brackmann
Pageof 44